Downregulation of miR-363 increases drug resistance in cisplatin-treated HepG2 by dysregulating Mcl-1

Gene

Volumn 572, Issue 1, 2015, Pages 116-122

  Ou, Yangyang ^a   Zhai, Denggao ^a   Wu, Nan ^a   Li, Xiaoli ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Apoptosis; Cisplatin; HepG2 R; Mcl 1; MiR 363

Indexed keywords

CISPLATIN; MICRORNA; MICRORNA 363; PROTEIN BCL 2; UNCLASSIFIED DRUG; 3' UNTRANSLATED REGION; ANTINEOPLASTIC AGENT; MCL1 PROTEIN, HUMAN; MIRN363 MICRORNA, HUMAN; PROTEIN MCL 1;

3' UNTRANSLATED REGION; APOPTOSIS; ARTICLE; CANCER RESISTANCE; CELL VIABILITY; DOWN REGULATION; LIVER CELL CARCINOMA; MUTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; AGED; ANTAGONISTS AND INHIBITORS; CARCINOMA, HEPATOCELLULAR; CELL SURVIVAL; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; HEPG2 CELL LINE; HUMAN; LIVER NEOPLASMS; MIDDLE AGED; PATHOLOGY;

3' UNTRANSLATED REGIONS; AGED; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL SURVIVAL; CISPLATIN; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; MICRORNAS; MIDDLE AGED; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; UP-REGULATION;

EID: 84940592248     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2015.07.002     Document Type: Article

References (35)

1. Ahmad Z., Tang Z., Chen X., et al. Cisplatin loaded methoxy poly (ethylene glycol)-block-poly(l-glutamic acid-co-l-phenylalanine) nanoparticles against human breast cancer cell. Macromol. Biosci. 2014, 14:1337-1345.
2. Akagi H., Higuchi H., Hibi T., et al. Suppression of myeloid cell leukemia-1 (Mcl-1) enhances chemotherapy-associated apoptosis in gastric cancer cells. Gastric Cancer 2013, 16:100-110.
3. An J., Wang X., Yu Z., et al. Hexabromocyclododecane and polychlorinated biphenyls increase resistance of hepatocellular carcinoma cells to cisplatin through the phosphatidylinositol 3-kinase/protein kinase B pathway. Toxicol. Lett. 2014, 229:265-272.
4. Bao B., Ali S., Kong D., et al. Anti-tumor activity of a novel compound-CDF is mediated by regulating miR-21, miR-200, and PTEN in pancreatic cancer. PLoS One 2011, 6:e17850.
5. Calastretti A., Gatti G., Quaresmini C., Bevilacqua A. Down-modulation of Bcl-2 sensitizes PTEN-mutated prostate cancer cells to starvation and taxanes. Prostate 2014, 14:1411-1422.
6. Chen L., Bourguignon L.Y. Hyaluronan-CD44 interaction promotes c-Jun signaling and miRNA21 expression leading to Bcl-2 expression and chemoresistance in breast cancer cells. Mol. Cancer 2014, 13:52.
7. Cheng A.M., Byrom M.W., Shelton J., Ford L.P. Antisense inhibition of human miRNAs and indications for an involvement of miRNA in cell growth and apoptosis. Nucleic Acids Res. 2005, 33:1290-1297.
8. Cohen S.M., Lippard S.J. Cisplatin: from DNA damage to cancer chemotherapy. Prog. Nucleic Acid Res. Mol. Biol. 2001, 67:93-130.
9. Danial N.N. BCL-2 family proteins: critical checkpoints of apoptotic cell death. Clin. Cancer Res. 2007, 13:7254-7263.
10. Esaki T., Nakano S., Masumoto N., Fujishima H., Niho Y. Schedule-dependent reversion of acquired cisplatin resistance by 5-fluorouracil in a newly established cisplatin-resistant HST-1 human squamous carcinoma cell line. Int. J. Cancer 1996, 65:479-484.
11. Galluzzi L., Vitale I., Michels J., Brenner C., Szabadkai G., Harel-Bellan A., et al. Systems biology of cisplatin resistance: past, present and future. Cell Death Dis. 2014, 5:e1257.
12. Geserick P., Wang J., Feoktistova M., Leverkus M. The ratio of Mcl-1 and noxa determines ABT737 resistance in squamous cell carcinoma of the skin. Cell Death Dis. 2014, 5:e1412.
13. Kang M.H., Reynolds C.P. Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin. Cancer Res. 2009, 15:1126-1132.
14. Kerr S.H., Kerr D.J. Novel treatments for hepatocellular cancer. Cancer Lett. 2009, 286:114-120.
15. Lau W.Y., Lai E.C., Lau W.Y., Lai E.C. Hepatocellular carcinoma: current management and recent advances. Hepatobiliary Pancreat. Dis. Int. 2008, 7:237-257.
16. Letai A., Sorcinelli M.D., Beard C., Korsmeyer S.J. Antiapoptotic BCL-2 is required for maintenance of a model leukemia. Cancer Cell 2004, 6:241-249.
17. Liu N., Zuo C., Zhu H., et al. miR-942 decreases TRAIL-induced apoptosis through ISG12a downregulation and is regulated by AKT. Oncotarget 2014, 5:4959-4971.
18. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25:402-408.
19. Ma J., Guo R., Wang T., Pan X., Lei X. Let-7b binding site polymorphism in the B-cell lymphoma-extra large 3'UTR is associated with fluorouracil resistance of hepatocellular carcinoma. Mol. Med. Rep. 2015, 11:677-681.
20. Meng F., Cao B., Li H. Knockdown of mutated H-Ras V12 expression induces chemosensitivity of hepatocellular carcinoma cells to cisplatin treatment in vitro and in nude mouse xenografts. Oncol. Rep. 2014, 32:2023-2030.
21. Mojsa B., Lassot I., Desagher S. Mcl-1 ubiquitination: unique regulation of an essential survival protein. Cells 2014, 3:418-437.
22. Palve V., Mallick S., Ghaisas G., Kannan S., Teni T. Overexpression of Mcl-1L splice variant is associated with poor prognosis and chemoresistance in oral cancers. PLoS One 2014, 9:e111927.
23. Pan Y., Ren F., Feng Y., et al. Regulation of BGC-823 cell sensitivity to adriamycin via miRNA-135a-5p. Oncol. Rep. 2014, 32:2549-2556.
24. Peng X., Cao P., Cao K., et al. MiR-634 sensitizes nasopharyngeal carcinoma cells to paclitaxel and inhibits cell growth both in vitro and in vivo. Int. J. Clin. Exp. Pathol. 2014, 7:6784-6791.
25. Sun Q., Zhang J., Cao W., Wang X., Xu Q., Yan M., Wu X., Chen W. Dysregulated miR-363 affects head and neck cancer invasion and metastasis by targeting podoplanin. Int. J. Biochem. Cell Biol. 2013, 45:513-520.
26. Tong S.J., Liu J., Wang X., Qu L.X. microRNA-181 promotes prostate cancer cell proliferation by regulating DAX-1 expression. Exp. Ther. Med. 2014, 8:1296-1300.
27. Tsuji S., Kawasaki Y., Furukawa S., Taniue K., Hayashi T., Okuno M., Hiyoshi M., Kitayama J., Akiyama T. The miR-363-GATA6-Lgr5 pathway is critical for colorectal tumourigenesis. Nat. Commun. 2014, 5:3150.
28. Weecharangsan W., Lee R.J. Growth inhibition and chemosensitization of human carcinoma cells by human serum albumin-coated liposomal antisense oligodeoxyribonucleotide against bcl-2. Drug Deliv. 2012, 19:292-297.
29. Winter J., Jung S., Diederichs S., et al. Many roads to maturity: microRNA biogenesis pathways and their regulation. Nat. Cell Biol. 2009, 11:228-234.
30. Xie Q., Chen X., Lu F., et al. Aberrant expression of microRNA 155 may accelerate cell proliferation by targeting sex-determining region Y box 6 in hepatocellular carcinoma. Cancer 2012, 118:2431-2442.
31. Xu N., Zhang J., Shen C., Luo Y., Xia L., Xue F., Xia Q. Cisplatin-induced downregulation of miR-199a-5p increases drug resistance by activating autophagy in HCC cell. Biochem. Biophys. Res. Commun. 2012, 423:826-831.
32. Xu G., Yu H., Shao G., et al. Cisplatin sensitivity is enhanced in non-small cell lung cancer cells by regulating epithelial-mesenchymal transition through inhibition of eukaryotic translation initiation factor 5A2. BMC Pulm. Med. 2014, 14:174.
33. Zhang Y., Wei W., Cheng N., et al. Hepatitis C virus-induced up-regulation of microRNA-155 promotes hepatocarcinogenesis by activating Wnt signaling. Hepatology 2012, 56:1631-1640.
34. Zhou P., Huang G., Zhao Y., Zhong D., Xu Z., Zeng Y., Zhang Y., Li S., He F. MicroRNA-363-mediated downregulation of S1PR1 suppresses the proliferation of hepatocellular carcinoma cells. Cell. Signal. 2014, 26:1347-1354.
35. Zhu A.X. Systemic therapy of advanced hepatocellular carcinoma: how hopeful should we be?. Oncologist 2006, 11:790-800.